logo-loader
HealthPharma & Biotech
viewMaxCyte Inc

MaxCyte updates on plans to simplify share structure

MaxCyte currently has two classes of shares: unrestricted and Regulation S restricted

share certificate
The move is intended to help both trading liquidity and transparency for shareholders

MaxCyte (LON:MXCT) said from November 28 all common stock will be held as unrestricted shares as it provided an update on plans to merge two separate classes of equity.

The move is intended to help both trading liquidity and transparency for shareholders.

MaxCyte currently has two classes of shares: unrestricted and Regulation S restricted. For more information click here.

Quick facts: MaxCyte Inc

Price: 117.5 GBX

AIM:MXCT
Market: AIM
Market Cap: £67.43 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MaxCyte Inc gearing up for phase I study of potential cancer breakthrough

Doug Doerfler, chief executive of MaxCyte Inc (LON:MXCT), tells Proactive they're in a strong financial position as they prepare for the launch of a phase I clinical trial of a cancer treatment which helps to deploy the body’s own immune defences to combat strains of the killer...

on 23/1/18

2 min read